The company Eli Lilly & Co seeks to implement the drugs in alcohol, nicotine and drug abuse. Its biggest competitor announced that it is also conducting studies on addictions.
The pharmaceutical giant Eli Lilly & Cowill begin conducting studies to determine if its successful medications against obesity They are also equally effective in treating and controlling addictive behaviors such as drug addiction, smoking, alcohol abuse and others, as stated by his CEO, Dave Ricks.
These medications are “antihedonic“, meaning that it allows serotonin levels to remain longer, providing a feeling of well-being, which can give patients greater respite from your dependenceRicks said during an interview this Tuesday with David Rubenstein at a meeting of Economics Club in Washington DC.
Various authorities and personnel doctorsthey already trust the effectiveness of these injections to be able relieve cravingsas is the case of Novo Nordisk A/SLilly’s rival, which announced that from the beginning of 2024 they were also planning studies on addiction.
eli lilly & co Zepbound (1).png
Eli Lilly & Co
How these medications work
Eli Lilly produces the popular weight loss drug, Zepboundand suggest that “these drugs may be useful for others conditions that we don’t think about related to weight,” Ricks said, adding that they help reduce “that cycle of desire“present in the consumption of other substances.
“In it 2025 You will see how Lilly starts big studios in alcohol abuse and nicotine consumption, even in drug abuse“said the CEO of the pharmaceutical company, who communicates the news at a time when medications for thin they are very popular and defendants in the market.
This type of medication, recommended mainly for weight loss, belongs to the class known as GLP-1which mimic hormones that interact with a region of the brain that produces reduced appetite and causes a great satiety after eating.
Future trials and strong competition
Although they are still in the process of investigation and studies for next yearEli Lilly will be the first pharmaceutical company in conducting clinical trials specifically focused on direct addiction treatments, and will change the scope of current analyses.
However, his competitor Novo Nordiskalso joined the race for the development of tests and advances that manage to incorporate medications that work to combat different types of addictions and problematic.
Ricks also referred to the imbalance in the drug prices between the United States and other countries, where he stated that patients abroad should pay more for his medications. This argument had already been raised by the president-elect donald trump during his first term, which will probably return in future decisions, according to the CEO.
Source: Ambito
I am Pierce Boyd, a driven and ambitious professional working in the news industry. I have been writing for 24 Hours Worlds for over five years, specializing in sports section coverage. During my tenure at the publication, I have built an impressive portfolio of articles that has earned me a reputation as an experienced journalist and content creator.
